Biocom’s top priority is the safety of our members and the well-being of our employees. After careful consideration, Biocom has decided to transform our 2021 Global Life Science Partnering Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner.
Senior Vice President, Global Gene Therapy Business, Rare Disease, Global Innovation Pharma, Pfizer Inc.
Bob is an accomplished biopharmaceutical executive with over thirty years’ experience in a variety of academic, alliance management, business development, commercial, corporate, and research and development roles.
He is currently responsible for leading and managing the Worldwide Business Development activities for Pfizer’s Worldwide Research and Development organization. He is also responsible for leading and managing Pfizer’s Strategic Transactions team.
Bob joined Pfizer from Wyeth in October 2009, following Pfizer’s $68 billion acquisition of Wyeth, where he was responsible for leading and managing Wyeth’s Global Mergers and Acquisitions group. He was also responsible for the global mergers and acquisitions activities for Wyeth’s Consumer Healthcare division and its Fort Dodge Animal Health division.
Prior to this role, Bob was Senior Vice President, Global Licensing, Wyeth Pharmaceuticals, where he completed a wide variety of transactions in support of Wyeth’s commercial and research and development divisions.
Bob obtained a B.S. in Neuroscience from the University of Rochester and an M.B.A. in Finance and Corporate Accounting from the William E. Simon Graduate School of Business Administration at the University of Rochester, Rochester, New York.